The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Chronic Supplementation With a Mitochondrial Antioxidant (MitoQ) Improves Vascular Function in Healthy Older Adults
Open accessAbstract
Excess reactive oxygen species production by mitochondria is a key mechanism of age-related vascular dysfunction. Our laboratory has shown that supplementation with the mitochondrial-targeted antioxidant MitoQ improves vascular endothelial function by reducing mitochondrial reactive oxygen species and ameliorates arterial stiffening in old mice, but the effects in humans are unknown. Here, we sought to translate our preclinical findings to humans and determine the safety and efficacy of MitoQ. Twenty healthy older adults (60–79 years) with impaired endothelial function (brachial artery flow–mediated dilation <6%) underwent 6 weeks of oral supplementation with MitoQ (20 mg/d) or placebo in a randomized, placebo-controlled, double-blind, crossover design study. MitoQ was well tolerated, and plasma MitoQ was higher after the treatment versus placebo period ( P <0.05). Brachial artery flow–mediated dilation was 42% higher after MitoQ versus placebo ( P <0.05); the improvement was associated with amelioration of mitochondrial reactive oxygen species–related suppression of endothelial function (assessed as the increase in flow-mediated dilation with acute, supratherapeutic MitoQ [160 mg] administration; n=9; P <0.05). Aortic stiffness (carotid–femoral pulse wave velocity) was lower after MitoQ versus placebo ( P <0.05) in participants with elevated baseline levels (carotid–femoral pulse wave velocity >7.60 m/s; n=11). Plasma oxidized LDL (low-density lipoprotein), a marker of oxidative stress, also was lower after MitoQ versus placebo ( P <0.05). Participant characteristics, endothelium-independent dilation (sublingual nitroglycerin), and circulating markers of inflammation were not different (all P >0.1). These findings in humans extend earlier preclinical observations and suggest that MitoQ and other therapeutic strategies targeting mitochondrial reactive oxygen species may hold promise for treating age-related vascular dysfunction. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT02597023.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In humans, MitoQ improves vascular ageing in middle-aged and older adults (aged 60–79 years)286.”
From Mitochondrial and metabolic dysfunction in ageing and age-related diseases (2022) · cites this paper as [286]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association
Benjamin, E. J., Blaha, M. J., Chiuve, S. E., Cushman, M., Das, S. R., Deo, R., de Ferranti, S. D., Floyd, J., Fornage, M., Gillespie, C., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000485 · Cited by 12,591
Heidenreich, P. A., Trogdon, J. G., Khavjou, O. A., Butler, J., Dracup, K., Ezekowitz, M. D., Finkelstein, E. A., Hong, Y., Johnston, S. C., Khera, A., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31820a55f5 · Cited by 3,208
Anthropometric Standardization Reference Manual
Lohman, T. J., Roache, A. F., & Martorell, R. (1992) · Medicine & Science in Sports & Exercise · doi:10.1249/00005768-199208000-00020 · Cited by 2,764
Lakatta, E. G., & Levy, D. (2003) · Circulation · doi:10.1161/01.cir.0000048892.83521.58 · Cited by 2,244
Arterial Stiffness and Cardiovascular Events: The Framingham Heart Study
Mitchell, G. F., Hwang, S.-J., Vasan, R. S., Larson, M. G., Pencina, M. J., Hamburg, N. M., Vita, J. A., Levy, D., & Benjamin, E. J. (2010) · Circulation · doi:10.1161/circulationaha.109.886655 · Cited by 2,225
Long-term weight loss maintenance
Wing, R. R., & Phelan, S. (2005) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/82.1.222s · Cited by 1,941
Aortic Pulse Wave Velocity Improves Cardiovascular Event Prediction
Ben-Shlomo, Y., Spears, M., Boustred, C., May, M., Anderson, S. G., Benjamin, E. J., Boutouyrie, P., Cameron, J., Chen, C.-H., Cruickshank, J. K., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.09.063 · Cited by 1,835
The clinical implications of endothelial dysfunction
Widlansky, M. E., Gokce, N., Keaney, J. F., & Vita, J. A. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00994-x · Cited by 1,749
Hofstra, L., Tordoir, J. H. M., Kitslaar, P. J. E. H. M., Hoeks, A. P. G., & Daemen, M. J. A. P. (1996) · PubMed · doi:10.1161/01.cir.94.6.1283 · Cited by 1,603
Recommendations for Improving and Standardizing Vascular Research on Arterial Stiffness
Townsend, R. R., Wilkinson, I. B., Schiffrin, E. L., Avolio, A. P., Chirinos, J. A., Cockcroft, J. R., Heffernan, K. S., Lakatta, E. G., McEniery, C. M., Mitchell, G. F., et al. (2015) · Hypertension · doi:10.1161/hyp.0000000000000033 · Cited by 1,527
Cited by
Sorted by citations
Mitochondrial dysfunction: mechanisms and advances in therapy
Yao, Z., Li, H., Liao, P., Chen, L., Pan, Y., Zheng, Y., Zhang, C., Liu, D., Zheng, M., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01839-8 · Cited by 1,382
Mitochondrial and metabolic dysfunction in ageing and age-related diseases
Amorim, J. A., Coppotelli, G., Rolo, A. P., Palmeira, C. M., Ross, J. M., & Sinclair, D. A. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00626-7 · Cited by 990
Mitochondria in oxidative stress, inflammation and aging: from mechanisms to therapeutic advances
Xu, X., Pang, Y., & Fan, X. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02253-4 · Cited by 1,016
Mitochondria as a therapeutic target for common pathologies
Murphy, M. P., & Hartley, R. C. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.174 · Cited by 846
Self-citationAging and age‐related diseases: from mechanisms to therapeutic strategies
Li, Z., Zhang, Z., Ren, Y., Wang, Y., Fang, J., Yue, H., Ma, S., & Guan, F. (2021) · Biogerontology · doi:10.1007/s10522-021-09910-5 · Cited by 702
Metadata
- Authors
- Rossman, M. J., Santos-Parker, J. R., Steward, C. A. C., Bispham, N. Z., Cuevas, L. M., Rosenberg, H. L., Woodward, K. A., Chonchol, M., Gioscia-Ryan, R. A., Murphy, M. P., & Seals, D. R.
- Affiliations
- University of Colorado Boulder (US)
- From the Department of Integrative Physiology, University of Colorado Boulder (M.J.R., J.R.S.-P., C.A.C.S., N.Z.B., L.M.C., H.L.R., K.A.W., R.A.G.-R., D.R.S.)
- University of Colorado Anschutz (US)
- MRC Mitochondrial Biology Unit (GB)
- ORCID
- Venue
- Hypertension
- Published
- 2018-06
- Volume
- 71
- Issue
- 6
- Pages
- 1056-1063
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- PMC
- PMC5945293
- OpenAlex
- W2796629168
- Cited by
- 456
- References
- 42
- Citations by year
- 2026: 71 · 2025: 48 · 2024: 55 · 2023: 54 · 2022: 65 · 2021: 54 · 2020: 58 · 2019: 38 · 2018: 12
- FWCI
- 30.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Hypertension (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Apollo
- Funders
- Wellcome Trust (110158/Z/15/Z, 110159/Z/ 15/Z, /Z/15/Z)
- Georgia Clinical and Translational Science Alliance (UL1TR001082)
- National Institutes of Health (UL1TR001082, AG000279)
- University of Colorado Boulder (UL1 TR001082)
- Medical Research Council (MC_UU_00015/3, MC-U105663142)
- National Institute on Aging (R21AG049451, F32AG053009, T32AG000279)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK048520)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
- Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Keywords
- MitoQ, mitochondria-targeted antioxidants, mitochondrial reactive oxygen species, endothelial function, flow-mediated dilation, arterial stiffness, pulse wave velocity, oxidative stress, oxidized LDL, aging, older adults, vascular dysfunction, dietary supplementation
- MeSH terms
- Aged, Antioxidants, Brachial Artery, Double-Blind Method, Endothelium, Vascular, Female, Follow-Up Studies, Humans, Male, Middle Aged, Mitochondria, Vasodilation, Reactive Oxygen Species, Oxidative Stress, Cross-Over Studies, Dietary Supplements, Vascular Stiffness, Healthy Volunteers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
